Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Goldman Sachs, J.P. Morgan, Nordea, Morgan Stanley and DNB Markets in connection with Millicom’s rights issue
Mandate

Vinge advises Goldman Sachs, J.P. Morgan, Nordea, Morgan Stanley and DNB Markets in connection with Millicom’s rights issue

June 23, 2022 Capital Markets and Public M&A

Vinge advises Goldman Sachs International, J.P. Morgan Securities plc, Nordea Bank Abp, filial i Sverige (Joint Global Coordinators and Joint Bookrunners), DNB Markets, a part of DNB Bank ASA, Sweden Branch and Morgan Stanley & Co. International plc (Joint Bookrunners) in connection with Millicom International Cellular S.A.’s rights issue of approximately SEK 7.5 billion before issue costs.

Millicom’s shares are, through SDRs, listed on Nasdaq Stockholm. Millicom’s shares are directly listed on the Nasdaq Stock Market’s Global Select Market in the United States.

Vinge’s team primarily consist of David Andersson, William Kåge, Michaela Ådén and Erik Sjöman.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026